Posted in | News | Medical Robotics

Study Confirms Safety and Feasibility of Magellan Robotic System in TACE Procedures

Hansen Medical, Inc. -- An abstract accepted for presentation at the 40th Annual Society of Interventional Radiology (SIR) Meeting (February 28 - March 5, 2015, Atlanta, GA), found the use of the Magellan™ Robotic System in transarterial chemoembolization (TACE) procedures is feasible, and that remote robotic catheter navigation with Magellan leads to over 80% reduction in radiation dose to the operating physician when compared with a bedside control.

Lead investigator Dr. Sandeep Rao, MD, MBA authored the abstract, which reviewed the results of seven patients treated with robot-assisted TACE using the Magellan 6Fr Robotic Catheter over a 5 month period at Sierra Medical Center in El Paso, Texas.

Technical success of TACE with drug eluting beads was 100%. No major or access site complications were encountered. Average radiation exposure to the operator, as measured by RaySafe radiation monitoring, was reduced by over 80% using remote, robotic catheter navigation with Magellan when compared with the control site at the patient's bedside. Dr. Rao concluded that "The Magellan Robotic System is safe and feasible for routine use in transarterial chemoembolization." Dr. Rao will present his findings on Monday, March 2, 2015 at 5:10pm during the "Emerging Concepts" session at SIR 2015.

"Radiation exposure during complex embolization procedures is a serious occupational hazard for interventionalists, and physician societies such as SIR are increasingly focusing on efforts to educate their members and reduce exposure," said Cary Vance, President and CEO of Hansen Medical. "We applaud the work done by Dr. Rao to demonstrate the potential benefits of Magellan in TACE, which is the most common embolization procedure performed by Interventional Radiologists worldwide."

TACE is a minimally-invasive procedure involving catheter-based delivery of small embolic materials into selected, small arteries to deliver targeted chemotherapy and cut off the blood supply feeding a tumor in the liver. Approximately 175,000 TACE procedures are performed worldwide each year.1 TACE is most often performed in patients with Hepatocellular Carcinoma (HCC), which is the 5th most common cancer and the 3rd leading cause of cancer deaths in the US. The expected radiation dose rate to the operator in TACE procedures is approximately 4x higher than that in cardiac intervention, due to the larger imaging field size.2 Interventional Radiologists at several centers in the US and Europe are performing TACE procedures with the Magellan Robotic System.

"This study provides an excellent foundation for use of intravascular robotics in TACE procedures," said Dr. Rao, an Interventional Radiologist with Sierra Providence Health Network. "Robotic catheters have the potential to provide physicians with enhanced control in tortuous blood vessels; and the stability of the Magellan Robotic Catheter can help to ensure precise and targeted delivery of embolic materials, which is a critical part of these procedures."

About the Magellan™ Robotic System

Hansen Medical's Magellan Robotic System is intended to be used to facilitate navigation in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan Robotic System is designed to deliver predictability, control and catheter stability to endovascular procedures. Since its commercial introduction in the U.S. and Europe, the Magellan Robotic System has demonstrated its clinical versatility in many cases in a broad variety of peripheral vascular procedure types in centers across the U.S. and Europe. The Magellan Robotic System offers several important features including:

  • Provides predictability, control and catheter stability as a physician navigates a patient's peripheral vasculature and then provides a conduit for manual treatment of vascular disease with standard therapeutic devices.
  • Is designed to enable more predictable procedure times and increased case throughput potentially allowing hospitals to improve utilization within their vascular business line.
  • Employs an open architecture designed to allow for the subsequent use of many therapeutic devices on the market today.
  • Is designed to potentially reduce physician radiation exposure and fatigue by allowing the physician to navigate procedures while seated comfortably at a remote workstation away from the radiation field and without wearing heavy lead as required in conventional endovascular procedures.
  • The Magellan 9Fr Robotic Catheter allows for independent, robotic control of the distal tip of two telescoping catheters (an outer Guide and an inner Leader catheter), as well as robotic manipulation of standard guide wires.
  • The Magellan 6Fr Robotic Catheter allows for independent robotic control of two separate bend sites on a single catheter, as well as robotic manipulation of standard guide wires. This smaller catheter design may be preferred by certain physicians who prefer a smaller diameter vessel access site, or in procedures in smaller vessels.



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Auris Surgical Robotics Inc.. (2019, February 19). Study Confirms Safety and Feasibility of Magellan Robotic System in TACE Procedures. AZoRobotics. Retrieved on May 22, 2024 from

  • MLA

    Auris Surgical Robotics Inc.. "Study Confirms Safety and Feasibility of Magellan Robotic System in TACE Procedures". AZoRobotics. 22 May 2024. <>.

  • Chicago

    Auris Surgical Robotics Inc.. "Study Confirms Safety and Feasibility of Magellan Robotic System in TACE Procedures". AZoRobotics. (accessed May 22, 2024).

  • Harvard

    Auris Surgical Robotics Inc.. 2019. Study Confirms Safety and Feasibility of Magellan Robotic System in TACE Procedures. AZoRobotics, viewed 22 May 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.